Company Overview and News

 
Eventbrite surges in market debut

2h thestar
This copy is for your personal non-commercial use only. To order presentation-ready copies of Toronto Star content for distribution to colleagues, clients or customers, or inquire about permissions/licensing, please go to: www.TorontoStarReprints.com
EB DTK

 
Industrials lead Dow to record high; tech boosts S&P, Nasdaq

5h thestar.com.my
Dow hits record: The closing numbers are displayed after the closing bell of the Dow Industrial Average at the New York Stock Exchange yesterdy, September 20, 2018 in New York.. - AFP
DTK

15
Commentary: Alibaba's most innovative move to date? Jack Ma's graceful corporate exit

5h channelnewsasia
In another display of being ahead of the curve, Ma shifts from dynastic leadership to professional management to sustain his legacy.
GEC GE DTK GNE

 
Washington Real Estate Investment Trust Confirms 3rd Quarter 2018 Earnings Release Date and Conference Call Information

7h globenewswire
WASHINGTON, Sept. 20, 2018 (GLOBE NEWSWIRE) -- Washington REIT (Washington Real Estate Investment Trust – NYSE: WRE), a leading owner of commercial and multifamily properties in the Washington, DC area, will announce 3rd Quarter 2018 earnings in a press release to be issued on Thursday, October 25, 2018, after the U.S. market close.
DTK WRE

 
Eventbrite IPO: EB Stock at $36 Out of the Gate

8h investorplace
The Eventbrite IPO rolled out on Thursday, Sept. 20 with the stock selling under the EB symbol and it kicked off its public offering with a bang, listing itself in the New York Stock Exchange.
DTK

2
Journey To A Global Databank: Piecing Together The Puzzle

8h seekingalpha
I believe you cannot have a global databank unless you have a way to hold your fungible digital assets: that is, custody.
ICE DTK

1
Animal health firm Elanco surges 41 percent on debut

10h channelnewsasia
Elanco Animal Health's shares climbed 36 percent in their stock market debut on Thursday, in a sign of investor enthusiasm for the fast-growing pet healthcare market.
PFZ DTK MS 500680 PFE PFIZER

1
REFILE-Animal health firm Elanco surges 36 pct in debut

10h reuters
Sept 20 (Reuters) - Elanco Animal Health’s shares climbed 36 percent in their stock market debut on Thursday, in a sign of investor enthusiasm for the fast-growing pet healthcare market.
PFZ DTK MS 500680 PFE PFIZER

1
Animal health firm Elanco surges 41 percent on debut

10h reuters
(Reuters) - Eli Lilly unit Elanco Animal Health Inc’s (ELAN.N) shares jumped as much as 41 percent on their stock market debut on Thursday, adding to investor enthusiasm for the fast-growing pet healthcare market.
PFZ DTK MS 500680 PFE PFIZER

1
Animal health firm Elanco surges 36 percent in debut

12h channelnewsasia
Elanco Animal Health's shares climbed 36 percent in their stock market debut on Thursday, in a sign of investor enthusiasm for the fast-growing pet healthcare market.
PFZ DTK MS 500680 PFE PFIZER

1
Animal health firm Elanco surges 36 percent in debut

12h reuters
(Reuters) - Elanco Animal Health’s (ELAN.N) shares climbed 36 percent in their stock market debut on Thursday, in a sign of investor enthusiasm for the fast-growing pet healthcare market.
PFZ DTK MS 500680 PFE PFIZER

 
Elanco Animal Health stock soars more than 35% in trading debut

12h marketwatch
Elanco Animal Health Inc. shares ELAN, +0.34% soared more than 35% Thursday in their trading debut, after the company priced the stock above its price range. Elanco, a spinoff from Eli Lilly & Co. LLY, +0.16% issued 62.9 million shares at $24 each, compared with a price range of $20 to $23, to raise $1.51 billion. Goldman Sachs. J.P. Morgan and Morgan Stanley were book-running managers on the deal.
DTK MS

2
Eli Lilly Prices Animal Health Unit IPO at $24 Per Share

12h zacks
Eli Lilly & Company (LLY - Free Report) has priced the initial public offering of its Animal Health unit – Elanco - at $24 per share. The share price was above the expected range of $20-$23 per share.
NVS DTK ZTS PFE

3
Not Just Pocket Change: China's Hillhouse Capital's New Fund Has $10.6 Billion to Invest

14h biospace
China’s Hillhouse Capital Group, an equity investment firm, has a new fund, Hillhouse Fund IV, with $10.6 billion ready to invest. The close of this new fund makes it the biggest capital raise by a private-equity company in Asia.
YUMC UBX JUNO DTK

1
Just Energy Group Inc. Announces United States Court of Appeal for the Second Circuit Affirms Just Energy’s Use of the Outside Sales Exemption

14h globenewswire
TORONTO, Sept. 20, 2018 (GLOBE NEWSWIRE) -- Just Energy Group Inc. (“Just Energy” or the "Company"), a leading consumer company, specializing in electricity and natural gas commodities, energy efficiency solutions, and renewable energy options, is pleased to announce that in Kevin Flood, et al. v. Just Energy Marketing Group, et al. 2d Cir., No. 17-0546, the United States Court of Appeals for the Second Circuit yesterday affirmed the lower court’s decision holding that the plaintiffs fit the “outside salesman” exemption under the Fair Labor Standards Act (“FLSA”) and New York Labor Law (“NYLL”).
JE JE DTK

Related Articles

RIGL: Rigel Pharmaceuticals Analysis and Research Report

2018-09-18 - Asif

Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...

EKSO: Ekso Bionics Holdings Analysis and Research Report

2018-09-18 - Asif

Overview The company design, develop and sell exoskeleton technology to augment human strength, endurance and mobility. The company's exoskeleton technology serves multiple markets and can be used both by able-bodied users as well as by persons with physical disabilities. Ekso Bionics has sold, rented or leased devices that (a) enable individuals with neurological conditions affecting gait (stroke and spinal cord injury) to rehabilitate and to walk again and (b) allow industrial workers to perform heavy duty work for extended periods. Today, its medical exoskeleton, Ekso GT, is used as a rehabilitation tool to allow physicians and therapists to rehabilitate patients who have suffered a stroke or spinal cord injury. With its unique features designed specifically for hospitals and its proprietary SmartAssist software, Ekso GT allows for the early mobilization of patients, with high step count and high dosage treatments. The intent is to allow the patient’s central nervous syst...

AGRX: Agile Therapeutics Analysis and Research Report

2018-09-18 - Asif

Overview Agile Therapeutics is a forward-thinking women’s healthcare company dedicated to fulfilling the unmet health needs of today’s women. Twirla® and its other current potential product candidates are designed to provide women with contraceptive options that offer greater convenience and facilitate compliance. The company's lead product candidate, Twirla, also known as AG200-15, is a once-weekly prescription contraceptive patch that is at the end of Phase 3 clinical development. Since its inception in 1997, Agile Therapeutics has devoted substantial resources to developing Twirla, building its intellectual property portfolio, business planning, raising capital and providing general and administrative support for these operations. The company incurred research and development expenses of $14.4 million, $20.9 million and $25.6 million during the years ended December 31, 2017, 2016 and 2015, respectively. The company incurred research and development expenses of $2.4 milli...

Silicon Investor Message Boards

This table lists all message boards related to DTK / Deutsche Bank Contingent Capital Trust III on message board site Silicon Investor.

Medtech Inc (MDTK) Medtech Inc (MDTK) Medtech Inc (MDTK) MDTK-Medical Solutions for the Internet MDTK-Medical Solutions for the Internet MDTK-Medical Solutions for the Internet
idtk smartcard security finally perfected idtk smartcard security finally perfected idtk smartcard security finally perfected Pacific Diagnostic Technologies (PDTK) Pacific Diagnostic Technologies (PDTK) Pacific Diagnostic Technologies (PDTK)